138588-57-5

Usage

Uses

Used in Pharmaceutical Research:
[1,1'-Biphenyl]-4-amine, 2,4'-dichlorois used as a starting material for the synthesis of biologically active compounds in pharmaceutical research. Its unique chemical structure allows for the development of new drugs with potential therapeutic applications.
Used in Organic Synthesis:
In the field of organic synthesis, [1,1'-Biphenyl]-4-amine, 2,4'-dichlorois used as a building block for creating more complex molecules. Its reactivity and functional groups make it a versatile component in the synthesis of various organic compounds.
Used in Pesticide Development:
[1,1'-Biphenyl]-4-amine, 2,4'-dichlorois used as a chemical intermediate in the development of new pesticides. Its properties can be exploited to create effective and targeted pest control agents.
Used in Materials Science:
In the field of materials science, [1,1'-Biphenyl]-4-amine, 2,4'-dichlorois used for incorporating specific properties or functions into polymers and other materials. Its chemical structure can enhance the performance of these materials in various applications.

Upstream product

• 1679-18-1 4-Chlorophenylboronic acid 
• 135050-44-1 3-chloro-4-iodoaniline 
• 21402-26-6 4-bromo-3-chloroaniline 
• 138588-58-6 2,4'-dichloro-4-nitro-biphenyl 

Downstream Products

• 34883-43-7 2,4'-dichlorobiphenyl 
• 1415127-43-3 3-(5-(5-chloro-2-(((2,4'-dichloro-[1,1'-biphenyl]-4-yl)amino)methyl)phenyl)picolinamido)propanoic acid 
• 1414931-74-0 methyl 2'-(((2,4'-dichloro-[1,1'-biphenyl]-4-yl)amino)methyl)-3'-methoxy-5'-(trifluoromethyl)-[1,1'-biphenyl]-4-carboxylate 
• 1414931-83-1 2'-(((2,4'-dichloro-[1,1'-biphenyl]-4-yl)amino)methyl)-3'-methoxy-5'-(trifluoromethyl)-[1,1'-biphenyl]-4-carboxylic acid 
• 1414931-75-1 Ethyl 3-(2'-(((2,4'-dichloro-[1,1'-biphenyl]-4-yl)amino)methyl)-3'-methoxy-5'-(trifluoromethyl)-[1,1'-biphenyl]-4-ylcarboxamido)propanoate 
• 1414931-41-1 3-(2'-(((2,4'-dichloro-[1,1'-biphenyl]-4-yl)amino)methyl)-3'-methoxy-5'-(trifluoromethyl)-[1,1'-biphenyl]-4-ylcarboxamido)propanoic acid 

Relevant academic research and scientific papers

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

COMBINATION THERAPIES FOR TREATMENT OF CANCER

Combination therapies for treatment of cancers associated with mutations in the KRAS gene are provided. Compositions comprising therapeutic agents for treatment of cancers associated with mutations in the KRAS gene are also provided.

INHIBITORS OF KRAS G12C

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R1, R2a, R3a, R3b, R4a, R4b, G1, G2, L1, L2, m1, m2, A, B, W, X, Y, Z and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

BIPHENYL DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS

The present invention is directed to biphenyl derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.

PICOLINAMIDO-PROPANOIC ACID DERIVATIVES USEFUL AS GLUCAGON RECEPTOR ANTAGONISTS

The present invention is directed to picolanmido-propanoic acid derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.